Share-based Payment Arrangement, Expense of BridgeBio Oncology Therapeutics, Inc. from 30 Sep 2024 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
BridgeBio Oncology Therapeutics, Inc. annual and quarterly Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2024 to 31 Dec 2025.
  • BridgeBio Oncology Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $1,425,000, a 86% increase year-over-year.
  • BridgeBio Oncology Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $5,873,000, a 33% increase from 2024.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)

BridgeBio Oncology Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $5,873,000 +$1,448,000 +33% 01 Jan 2025 31 Dec 2025 10-K 05 Mar 2026 2025 FY
2024 $4,425,000 01 Jan 2024 31 Dec 2024 10-K 05 Mar 2026 2025 FY

BridgeBio Oncology Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,425,000 +$657,000 +86% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $768,000 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
* An asterisk sign (*) next to the value indicates that the value is likely invalid.